DISCLOSURE: This site receives compensation from featured companies, which may influence rankings. Read Advertising Disclosure
CJC-1295/Ipamorelin
compoundedCompounded — not FDA-approved. CJC-1295 and Ipamorelin are compounded peptides that have not been approved by the FDA for any therapeutic indication.
Est. Cost
$200 - $400/mo
/month
CJC-1295/Ipamorelin is a combined peptide protocol that pairs two growth hormone-stimulating peptides working through complementary mechanisms. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog with a significantly longer half-life than sermorelin, meaning it may sustain growth hormone release over a longer period. Ipamorelin is a ghrelin mimetic that stimulates GH release through a different receptor pathway, with the notable characteristic of not significantly increasing cortisol or prolactin in most individuals. Together, the stack is considered one of the more potent peptide approaches to growth hormone optimization. Both are compounded and not FDA-approved.
Dosage Format
Typical protocols involve subcutaneous injection, often dosed at bedtime. Common dosing includes 100-300mcg of each peptide, 5-6 nights per week. CJC-1295 with DAC may require less frequent dosing (1-2 times per week) due to its longer half-life. Protocols are individualized by the prescribing provider.
Type
Compounded
Best For
Adults interested in a more potent growth hormone stimulation protocol than sermorelin alone, targeting body composition, recovery, and anti-aging under physician supervision
Key Benefit
CJC-1295/Ipamorelin combines two peptides that stimulate growth hormone release through different receptors, which may produce a stronger and more sustained GH pulse than either peptide alone.
Where to Get CJC-1295/Ipamorelin
Compare providers offering cjc-1295/ipamorelin — ranked by our editorial team
Tailor Made Compounding
503B outsourcing facility — requires prescribing provider. Available as individual vials or combined formulation. Compounded, not FDA-approved.
$200 - $350/mo (via provider)
/month
Defy Medical
Individualized GH peptide protocol with required lab work and monitoring. Consultation fees separate. Compounded, not FDA-approved.
$200 - $350/mo + consultation
/month
Viking Alternative Medicine
Available as part of comprehensive optimization protocols. May be combined with HRT. Compounded, not FDA-approved.
$150 - $300/mo
/month
AgelessRx
Availability may vary. All-inclusive pricing when available. Compounded, not FDA-approved.
$200 - $350/mo
/month
How CJC-1295/Ipamorelin Works
CJC-1295 mimics GHRH and stimulates the pituitary gland to release growth hormone. Its engineered longer half-life (particularly the DAC variant) allows for fewer injections while maintaining elevated GH levels over several days. Ipamorelin acts on ghrelin receptors in the pituitary, providing a second stimulation pathway for GH release. When combined, these two peptides may produce a more robust and sustained growth hormone pulse than either alone. The resulting GH elevation may support protein synthesis, fat metabolism, recovery from exercise, sleep quality, and tissue repair. Because both work through the body's own pituitary, the risk of supraphysiologic GH levels is considered lower than with direct HGH injection, though monitoring is still recommended.
Side Effects
Common
- • Injection site reactions (redness, discomfort, swelling)
- • Water retention — particularly during initial weeks
- • Numbness or tingling in hands and fingers
- • Headache
- • Increased hunger (ipamorelin-related ghrelin effect)
- • Fatigue or vivid dreams during sleep cycle adjustment
Serious (Rare)
- • Joint pain or carpal tunnel symptoms if GH levels become significantly elevated
- • Allergic reaction — seek medical attention for severe swelling, difficulty breathing, or rash
- • Should not be used by individuals with active cancer — growth hormone stimulation may promote tumor growth
- • Potential interactions with insulin and diabetic medications — close monitoring required
Who Is Eligible
CJC-1295/Ipamorelin is generally prescribed to adults with declining growth hormone levels who are looking for a more potent GH-stimulating protocol. It is typically not appropriate for individuals with active cancer, uncontrolled diabetes, pituitary disorders, or certain cardiovascular conditions. Baseline blood work — particularly IGF-1 levels, fasting glucose, and metabolic panels — is commonly required. This is a compounded medication and is not FDA-approved.